
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Windtree Therapeutics Inc (WINT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: WINT (1-star) is a SELL. SELL since 1 days. Profits (-56.30%). Updated daily EoD!
1 Year Target Price $4
1 Year Target Price $4
0 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -90.19% | Avg. Invested days 12 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.15M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.63 | 52 Weeks Range 0.36 - 662.00 | Updated Date 08/15/2025 |
52 Weeks Range 0.36 - 662.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6321.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.2% | Return on Equity (TTM) -124.86% |
Valuation
Trailing PE - | Forward PE 0.37 | Enterprise Value 6557844 | Price to Sales(TTM) 660.53 |
Enterprise Value 6557844 | Price to Sales(TTM) 660.53 | ||
Enterprise Value to Revenue 706.08 | Enterprise Value to EBITDA 0.01 | Shares Outstanding 11908300 | Shares Floating 3661289 |
Shares Outstanding 11908300 | Shares Floating 3661289 | ||
Percent Insiders - | Percent Institutions 0.18 |
Upturn AI SWOT
Windtree Therapeutics Inc

Company Overview
History and Background
Windtree Therapeutics, Inc. was founded in 1992. Initially focused on surfactant therapies for respiratory distress syndrome (RDS) in premature infants, the company has evolved to focus on developing novel therapies for acute respiratory conditions.
Core Business Areas
- Aerosurf: Aerosurf is a novel, investigational combination drug/device product that delivers aerosolized KL4 surfactant to premature infants with respiratory distress syndrome (RDS) without intubation.
- ISTR: ISTR is focused on developing products addressing acute pulmonary conditions. Windtree is developing AEROSURF for use in neonates with respiratory distress syndrome (RDS), as well as rostafuroxin for cardiogenic shock.
Leadership and Structure
Craig Fraser is the President & CEO. The organizational structure consists of functional departments such as research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Aerosurf: Aerosurf is an investigational drug/device combination for RDS in premature infants. Since the product is not yet approved, there is no current market share. Competitors in the RDS market include Mallinckrodt (INOpulse), and various forms of traditional surfactant administration.
- Rostafuroxin: Rostafuroxin is a novel treatment for cardiogenic shock. Since the product is not yet approved, there is no current market share. Competitors include existing inotropic agents.
Market Dynamics
Industry Overview
The pharmaceutical industry is intensely competitive and fragmented. The market for acute respiratory therapies is driven by unmet medical needs and technological advancements.
Positioning
Windtree Therapeutics is positioned as a specialty pharmaceutical company focused on innovative therapies for respiratory conditions. Their competitive advantage lies in their novel surfactant technology and targeted therapeutic approach.
Total Addressable Market (TAM)
The TAM for RDS and cardiogenic shock is significant, estimated to be in the billions of dollars. Windtree aims to capture a portion of this market with its innovative products, but the precise TAM is dependent on approval and adoption rates.
Upturn SWOT Analysis
Strengths
- Novel surfactant technology (KL4)
- Potential for non-invasive treatment of RDS
- Experienced leadership team
- Focus on unmet medical needs
Weaknesses
- Reliance on successful clinical trials
- Limited financial resources
- Dependence on regulatory approval
- Small market capitalization
Opportunities
- Expanding indications for surfactant technology
- Partnerships with larger pharmaceutical companies
- Orphan drug designation benefits
- Advancements in drug delivery systems
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Economic downturns impacting funding
Competitors and Market Share
Key Competitors
- MNK (Mallinckrodt)
- RDHL (Redhill Biopharma Ltd.)
- INSYS
Competitive Landscape
Windtree faces intense competition from established pharmaceutical companies with approved therapies. Their advantage lies in their innovative technology, but they must overcome significant regulatory and commercial hurdles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the lack of approved products. The company's growth is tied to the successful development and commercialization of its pipeline.
Future Projections: Future growth depends on clinical trial outcomes and regulatory approvals. Analyst projections are highly variable and dependent on these factors.
Recent Initiatives: Recent initiatives include advancing Aerosurf clinical trials, seeking regulatory approvals, and exploring potential partnerships.
Summary
Windtree Therapeutics is a development-stage pharmaceutical company with innovative technology targeting respiratory conditions. While its novel surfactant technology holds promise, the company faces challenges related to clinical trial success, regulatory approval, and securing funding. The lack of approved products makes it a higher-risk investment, and it must capitalize on partnership opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Windtree Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Windtree Therapeutics Inc
Exchange NASDAQ | Headquaters Warrington, PA, United States | ||
IPO Launch date 1995-08-08 | CEO, President & Director Mr. Jed A. Latkin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://windtreetx.com |
Full time employees 14 | Website https://windtreetx.com |
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.